Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Instil Bio, Inc.NASDAQ: TIL
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 23.6% from a year ago
Total equity stood at $110.7M at the end of Q1 FY2026, down 23.6% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at -32.1% a year.
Context
- Total equity amounted to 55.2% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -23.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 113.87M USD
- Year-over-year change
- -32.8%
- 4-year CAGR
- -32.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 113.87M | -32.8% |
| FY2024 | 2024-12-31 | 169.44M | -25.0% |
| FY2023 | 2023-12-31 | 225.83M | -37.9% |
| FY2022 | 2022-12-31 | 363.61M | -34.5% |
| FY2021 | 2021-12-31 | 555.2M | — |
Total Equity vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -23.6% is the 2nd highest of 9, against a peer median of -47.6%.
- Total equity amounts to 55.2% of total assets for TIL, versus a peer median of 78.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $182.68M USD | -38.2% | -20.7% | 72.2% | |
| Mar 2026 | $165.17M USD | -35.8% | -16.7% | 81.5% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $116.18M USD | -47.6% | -4.9% | 91.3% |
| Mar 2026 | $110.7M USD | -23.6% | -32.1% | 55.2% | |
| Mar 2026 | $95.84M USD | +41.8% | -22.4% | 93.8% | |
| Mar 2026 | €36.93M EUR | -47.6% | -22.2% | 75.5% | |
| Mar 2026 | $21.2M USD | -73.2% | -26.8% | 9.7% | |
| Mar 2026 | -CA$5.13M CAD | -179.0% | — | 62.9% | |
| Mar 2026 | -$278.15M USD | -5002.1% | — | 230.4% | |
| Peer median (excluding TIL) | — | -47.6% | -21.5% | 78.5% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37.59M | 43.72M | 9.2M | 8.81M | 6.64M |
| Short-term Investments | 416.51M | 217.2M | 141.16M | 104.51M | 69.49M |
| Net Receivables | 0 | 0 | 0 | 0 | 848K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8.46M | 1.5M | 1.83M | 112.41M |
| Total Current Assets | 464.02M | 269.38M | 160.76M | 124.47M | 191.43M |
| Property, Plant & Equipment (Net) | 122M | 209.34M | 141.07M | 130.34M | 364K |
| Goodwill | 5.72M | 0 | 0 | 0 | 0 |
| Intangible Assets | 10.1M | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 23.16M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8.14M | 3.41M | 639K | 8.76M | 11.73M |
| Total Non-current Assets | 145.96M | 212.75M | 164.87M | 139.1M | 12.09M |
| Total Assets | 609.98M | 482.13M | 325.63M | 263.57M | 203.52M |
| Account Payables | 5.57M | 2.36M | 1.21M | 659K | 779K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 524K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 13.66M | 4.23M | 1.22M | 2.07M | 2.52M |
| Total Current Liabilities | 41.36M | 32.79M | 10.56M | 7.9M | 4.84M |
| Long-term Debt | 0 | 72.35M | 81.43M | 84.19M | 84.81M |
| Deferred Tax Liabilities | 2.43M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 11M | 8.21M | 4.94M | 1.03M | 8K |
| Total Non-current Liabilities | 13.43M | 85.74M | 89.24M | 86.24M | 84.81M |
| Total Liabilities | 54.78M | 118.52M | 99.8M | 94.13M | 89.66M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (201.72M) | (424.89M) | (580.98M) | (655.12M) | (726.49M) |
| Accumulated OCI | (87K) | (493K) | (348K) | (228K) | (583K) |
| Other Stockholders Equity | 0 | 0 | 0 | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 555.2M | 363.61M | 225.83M | 169.44M | 113.87M |
| Total Debt | 0 | 79.9M | 86.05M | 86.89M | 85.18M |
| Net Debt | (37.59M) | 36.19M | 76.86M | 78.08M | 78.54M |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.